Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

The Eye Want 2 Know digital resource helps patients and their families in the U.S. living with an inherited retinal disease (IRD) learn about genetic testing and includes a “Find A Provider” tool to...
October 08, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

PHILADELPHIA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease,...
September 25, 2018 12:49 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Annuncia il Parere positivo del CHMP per la Terapia Genica una tantum LUXTURNA® (voretigene neparvovec) nell’Unione europea

LUXTURNA diventerebbe la prima terapia genica per una malattia genetica approvata sia negli USA sia nella UE LUXTURNA sarebbe la prima e unica terapia genica approvata nell’UE per il trattamento di...
September 25, 2018 12:49 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics gibt zustimmende Bewertung des Ausschusses für Humanarzneimittel für die einmalig verabreichte Gentherapie LUXTURNA® (Voretigen Neparvovec) in der Europäischen Union bekannt

LUXTURNA wäre die erste Gentherapie für eine genetische Erkrankung, die sowohl in den USA als auch in der EU zugelassen ist LUXTURNA wäre die erste und einzige...
September 21, 2018 07:17 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union

LUXTURNA would be first gene therapy for a genetic disease approved in both U.S. and EU LUXTURNA would be first and only gene therapy approved in EU to treat patients with vision loss due to...
August 07, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress

As of July 13, 2018, preliminary Phase 1/2 data for investigational SPK-8011 for hemophilia A show: A 97-percent reduction in annualized bleeding rate (ABR) and 97-percent reduction in annualized...
August 03, 2018 15:23 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics wurde vom Philadelphia Business Journal zum zweiten Mal in Folge als einer von Philadelphias „besten Arbeitgeber“ ausgezeichnet

PHILADELPHIA , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
August 03, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal

PHILADELPHIA, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
July 31, 2018 14:16 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics veranstaltet am Dienstag, 7. August, um 8.30 Uhr ET (Ostküstenzeit) eine Telefonkonferenz, um über die Unternehmens- und Finanzergebnisse des zweiten Quartals und die neuesten Geschäftserfolge zu sprechen

PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das infrage stellt, dass genetische Krankheiten unvermeidbar sind,...
July 31, 2018 07:30 ET | Source: Spark Therapeutics, Inc.

Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights

PHILADELPHIA, July 31, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...